메뉴 건너뛰기




Volumn 61, Issue , 2015, Pages 33-40

Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer

Author keywords

AntiCD40; Cancer immunotherapy; CTLA4 blocking antibody; Immunomodulatory antibody; Incomplete Freund's adjuvant (IFA); Local delivery; PLHMGA; Sustained release

Indexed keywords

DISEASES; EMULSIFICATION; MAMMALS; TUMORS;

EID: 84939151920     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.04.043     Document Type: Article
Times cited : (96)

References (59)
  • 1
    • 84890814629 scopus 로고    scopus 로고
    • Breakthrough of the year 2013. Cancer immunotherapy
    • Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013, 342:1432-1433.
    • (2013) Science , vol.342 , pp. 1432-1433
    • Couzin-Frankel, J.1
  • 2
    • 80053280757 scopus 로고    scopus 로고
    • Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines
    • Weir G.M., Liwski R.S., Mansour M. Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines. Cancers 2011, 3:3114-3142.
    • (2011) Cancers , vol.3 , pp. 3114-3142
    • Weir, G.M.1    Liwski, R.S.2    Mansour, M.3
  • 3
    • 84856342711 scopus 로고    scopus 로고
    • Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear
    • Dimberu P.M., Leonhardt R.M. Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear. Yale J. Biol. Med. 2011, 84:371-380.
    • (2011) Yale J. Biol. Med. , vol.84 , pp. 371-380
    • Dimberu, P.M.1    Leonhardt, R.M.2
  • 4
    • 84991035719 scopus 로고    scopus 로고
    • Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation
    • Vatsan R.S., Bross P.F., Liu K., Theoret M., De Claro A.R., Lu J., et al. Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation. J. Immunother. Cancer 2013, 1. 5-5.
    • (2013) J. Immunother. Cancer , vol.1 , pp. 5
    • Vatsan, R.S.1    Bross, P.F.2    Liu, K.3    Theoret, M.4    De Claro, A.R.5    Lu, J.6
  • 6
    • 77951614830 scopus 로고    scopus 로고
    • Monoclonal antibodies: versatile platforms for cancer immunotherapy
    • Weiner L.M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10:317-327.
    • (2010) Nat. Rev. Immunol. , vol.10 , pp. 317-327
    • Weiner, L.M.1    Surana, R.2    Wang, S.3
  • 7
    • 66849135251 scopus 로고    scopus 로고
    • Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
    • Peggs K.S., Quezada S.A., Allison J.P. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin. Exp. Immunol. 2009, 157:9-19.
    • (2009) Clin. Exp. Immunol. , vol.157 , pp. 9-19
    • Peggs, K.S.1    Quezada, S.A.2    Allison, J.P.3
  • 8
    • 33646794392 scopus 로고    scopus 로고
    • Checkpoint blockade in cancer immunotherapy
    • Korman A.J., Peggs K.S., Allison J.P. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 2006, 90:297-339.
    • (2006) Adv. Immunol. , vol.90 , pp. 297-339
    • Korman, A.J.1    Peggs, K.S.2    Allison, J.P.3
  • 9
    • 84858766182 scopus 로고    scopus 로고
    • The blockade of immune checkpoints in cancer immunotherapy
    • Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
    • (2012) Nat. Rev. Cancer , vol.12 , pp. 252-264
    • Pardoll, D.M.1
  • 10
    • 84892485531 scopus 로고    scopus 로고
    • Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer
    • Brahmer J.R., Pardoll D.M. Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol. Res. 2013, 1:85-91.
    • (2013) Cancer Immunol. Res. , vol.1 , pp. 85-91
    • Brahmer, J.R.1    Pardoll, D.M.2
  • 12
    • 38549089084 scopus 로고    scopus 로고
    • The reverse stop-signal model for CTLA4 function
    • Rudd C.E. The reverse stop-signal model for CTLA4 function. Nat. Rev. Immunol. 2008, 8:153-160.
    • (2008) Nat. Rev. Immunol. , vol.8 , pp. 153-160
    • Rudd, C.E.1
  • 13
    • 0029120245 scopus 로고
    • CD28 and CTLA-4 have opposing effects on the response of t-cells to stimulation
    • Krummel M.F., Allison J.P. CD28 and CTLA-4 have opposing effects on the response of t-cells to stimulation. J. Exp. Med. 1995, 182:459-465.
    • (1995) J. Exp. Med. , vol.182 , pp. 459-465
    • Krummel, M.F.1    Allison, J.P.2
  • 14
    • 81055127514 scopus 로고    scopus 로고
    • Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
    • 196-5876-9-196
    • Ascierto P.A., Marincola F.M., Ribas A. Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J. Transl. Med. 2011, 9. 196-5876-9-196.
    • (2011) J. Transl. Med. , vol.9
    • Ascierto, P.A.1    Marincola, F.M.2    Ribas, A.3
  • 15
    • 0036301503 scopus 로고    scopus 로고
    • CTLA-4: new insights into its biological function and use in tumor immunotherapy
    • Egen J.G., Kuhns M.S., Allison J.P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 2002, 3:611-618.
    • (2002) Nat. Immunol. , vol.3 , pp. 611-618
    • Egen, J.G.1    Kuhns, M.S.2    Allison, J.P.3
  • 16
    • 79954533158 scopus 로고    scopus 로고
    • Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
    • Quezada S.A., Peggs K.S., Simpson T.R., Allison J.P. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol. Rev. 2011, 241:104-118.
    • (2011) Immunol. Rev. , vol.241 , pp. 104-118
    • Quezada, S.A.1    Peggs, K.S.2    Simpson, T.R.3    Allison, J.P.4
  • 17
  • 18
    • 84873129546 scopus 로고    scopus 로고
    • CTLA-4 blockade in tumor models: an overview of preclinical and translational research
    • Grosso J.F., Jure-Kunkel M.N. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 2013, 13:5.
    • (2013) Cancer Immun. , vol.13 , pp. 5
    • Grosso, J.F.1    Jure-Kunkel, M.N.2
  • 19
    • 40949116644 scopus 로고    scopus 로고
    • Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody
    • Camacho L.H. Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody. Exp. Opin. Investig. Drugs 2008, 17:371-385.
    • (2008) Exp. Opin. Investig. Drugs , vol.17 , pp. 371-385
    • Camacho, L.H.1
  • 20
    • 53749087081 scopus 로고    scopus 로고
    • Anti-CTLA4 monoclonal antibody ipilimumab in the treatment of metastatic melanoma: Recent findings
    • Lens M., Ferrucci P.F., Testori A. Anti-CTLA4 monoclonal antibody ipilimumab in the treatment of metastatic melanoma: Recent findings. Recent Pat. Anticancer Drug Discov. 2008, 3:105-113.
    • (2008) Recent Pat. Anticancer Drug Discov. , vol.3 , pp. 105-113
    • Lens, M.1    Ferrucci, P.F.2    Testori, A.3
  • 21
    • 0035451607 scopus 로고    scopus 로고
    • The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity
    • Morel Y., Truneh A., Sweet R., Olive D., Costello R. The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity. J. Immunol. 2001, 167:2479-2486.
    • (2001) J. Immunol. , vol.167 , pp. 2479-2486
    • Morel, Y.1    Truneh, A.2    Sweet, R.3    Olive, D.4    Costello, R.5
  • 22
    • 0037117542 scopus 로고    scopus 로고
    • CD40 stimulation leads to effective therapy of CD40(-)tumors through induction of strong systemic cytotoxic T lymphocyte immunity
    • van Mierlo G., den Boer A., Medema J., van der Voort E., Fransen M., Offringa R., et al. CD40 stimulation leads to effective therapy of CD40(-)tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:5561-5566.
    • (2002) Proc. Natl. Acad. Sci. U. S. A. , vol.99 , pp. 5561-5566
    • van Mierlo, G.1    den Boer, A.2    Medema, J.3    van der Voort, E.4    Fransen, M.5    Offringa, R.6
  • 23
    • 0032482474 scopus 로고    scopus 로고
    • T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
    • Schoenberger S., Toes R., van der Voort E., Offringa R., Melief C. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998, 393:480-483.
    • (1998) Nature , vol.393 , pp. 480-483
    • Schoenberger, S.1    Toes, R.2    van der Voort, E.3    Offringa, R.4    Melief, C.5
  • 24
    • 33947506186 scopus 로고    scopus 로고
    • Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
    • Vonderheide R.H., Flaherty K.T., Khalil M., Stumacher M.S., Bajor D.L., Hutnick N.A., et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 2007, 25:876-883.
    • (2007) J. Clin. Oncol. , vol.25 , pp. 876-883
    • Vonderheide, R.H.1    Flaherty, K.T.2    Khalil, M.3    Stumacher, M.S.4    Bajor, D.L.5    Hutnick, N.A.6
  • 25
    • 24944459890 scopus 로고    scopus 로고
    • Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
    • Attia P., Phan G., Maker A., Robinson M., Quezado M., Yang J., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 2005, 23:6043-6053.
    • (2005) J. Clin. Oncol. , vol.23 , pp. 6043-6053
    • Attia, P.1    Phan, G.2    Maker, A.3    Robinson, M.4    Quezado, M.5    Yang, J.6
  • 26
    • 84874118594 scopus 로고    scopus 로고
    • Local targets for immune therapy to cancer: Tumor draining lymph nodes and tumor microenvironment
    • Fransen M.F., Arens R., Melief C.J.M. Local targets for immune therapy to cancer: Tumor draining lymph nodes and tumor microenvironment. Int. J. Cancer 2013, 132:1971-1976.
    • (2013) Int. J. Cancer , vol.132 , pp. 1971-1976
    • Fransen, M.F.1    Arens, R.2    Melief, C.J.M.3
  • 27
    • 84874845333 scopus 로고    scopus 로고
    • Agonistic CD40 antibodies and cancer therapy
    • Vonderheide R.H., Glennie M.J. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 2013, 19:1035-1043.
    • (2013) Clin. Cancer Res. , vol.19 , pp. 1035-1043
    • Vonderheide, R.H.1    Glennie, M.J.2
  • 28
    • 33747878218 scopus 로고    scopus 로고
    • Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma
    • Maker A., Yang J., Sherry R., Topalian S., Kannula U., Royal R., et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J. Immunother. 2006, 29:455-463.
    • (2006) J. Immunother. , vol.29 , pp. 455-463
    • Maker, A.1    Yang, J.2    Sherry, R.3    Topalian, S.4    Kannula, U.5    Royal, R.6
  • 29
    • 84890281406 scopus 로고    scopus 로고
    • Adverse events to monoclonal antibodies used for cancer therapy Focus on hypersensitivity responses
    • Baldo B.A. Adverse events to monoclonal antibodies used for cancer therapy Focus on hypersensitivity responses. Oncoimmunol 2013, 2.
    • (2013) Oncoimmunol , vol.2
    • Baldo, B.A.1
  • 30
    • 20044395957 scopus 로고    scopus 로고
    • Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma
    • Sanderson K., Scotland R., Lee P., Liu D., Groshen S., Snively J., et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 2005, 23:741-750.
    • (2005) J. Clin. Oncol. , vol.23 , pp. 741-750
    • Sanderson, K.1    Scotland, R.2    Lee, P.3    Liu, D.4    Groshen, S.5    Snively, J.6
  • 31
    • 84886427186 scopus 로고    scopus 로고
    • Controlled local delivery of CTLA-4 blocking antibody induces cd8(+) t-cell-dependent tumor eradication and decreases risk of toxic side effects
    • Fransen M.F., van der Sluis T.C., Ossendorp F., Arens R., Melief C.J.M. Controlled local delivery of CTLA-4 blocking antibody induces cd8(+) t-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin. Cancer Res. 2013, 19:5381-5389.
    • (2013) Clin. Cancer Res. , vol.19 , pp. 5381-5389
    • Fransen, M.F.1    van der Sluis, T.C.2    Ossendorp, F.3    Arens, R.4    Melief, C.J.M.5
  • 32
    • 79954579274 scopus 로고    scopus 로고
    • Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody
    • Fransen M.F., Sluijter M., Morreau H., Arens R., Melief C.J. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin. Cancer Res. 2011, 17:2270-2280.
    • (2011) Clin. Cancer Res. , vol.17 , pp. 2270-2280
    • Fransen, M.F.1    Sluijter, M.2    Morreau, H.3    Arens, R.4    Melief, C.J.5
  • 33
    • 84939213332 scopus 로고    scopus 로고
    • A review of some cancer clinical trials with montanide ISA 51 vaccine adjuvant
    • Aucouturier J., Ascarateil S., O'Neill S. A review of some cancer clinical trials with montanide ISA 51 vaccine adjuvant. J. Immunother. 2003, 26:S45-S46.
    • (2003) J. Immunother. , vol.26 , pp. S45-S46
    • Aucouturier, J.1    Ascarateil, S.2    O'Neill, S.3
  • 34
    • 77957773809 scopus 로고    scopus 로고
    • Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity
    • Graham B.S., McElrath M.J., Keefer M.C., Rybczyk K., Berger D., Weinhold K.J., et al. Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS One 2010, 5:e11995.
    • (2010) PLoS One , vol.5 , pp. e11995
    • Graham, B.S.1    McElrath, M.J.2    Keefer, M.C.3    Rybczyk, K.4    Berger, D.5    Weinhold, K.J.6
  • 35
    • 84860556665 scopus 로고    scopus 로고
    • Controlled release of octreotide and assessment of peptide acylation from poly(d,l-lactide-co-hydroxymethyl glycolide) compared to plga microspheres
    • Ghassemi A.H., van Steenbergen M.J., Barendregt A., Talsma H., Kok R.J., van Nostrum C.F., et al. Controlled release of octreotide and assessment of peptide acylation from poly(d,l-lactide-co-hydroxymethyl glycolide) compared to plga microspheres. Pharm. Res. 2012, 29:110-120.
    • (2012) Pharm. Res. , vol.29 , pp. 110-120
    • Ghassemi, A.H.1    van Steenbergen, M.J.2    Barendregt, A.3    Talsma, H.4    Kok, R.J.5    van Nostrum, C.F.6
  • 36
    • 84864969640 scopus 로고    scopus 로고
    • The microclimate pH in poly(D,L-lactide-co-hydroxymethyl glycolide) microspheres during biodegradation
    • Liu Y., Ghassemi A.H., Hennink W.E., Schwendeman S.P. The microclimate pH in poly(D,L-lactide-co-hydroxymethyl glycolide) microspheres during biodegradation. Biomaterials 2012, 33:7584-7593.
    • (2012) Biomaterials , vol.33 , pp. 7584-7593
    • Liu, Y.1    Ghassemi, A.H.2    Hennink, W.E.3    Schwendeman, S.P.4
  • 37
    • 67650101251 scopus 로고    scopus 로고
    • Preparation and characterization of protein loaded microspheres based on a hydroxylated aliphatic polyester, poly (lactic-co-hydroxymethyl glycolic acid)
    • Ghassemi A.H., van Steenbergen M.J., Talsma H., van Nostrum C.F., Jiskoot W., Crommelin D.J.A., et al. Preparation and characterization of protein loaded microspheres based on a hydroxylated aliphatic polyester, poly (lactic-co-hydroxymethyl glycolic acid). J. Control Release 2009, 138:57-63.
    • (2009) J. Control Release , vol.138 , pp. 57-63
    • Ghassemi, A.H.1    van Steenbergen, M.J.2    Talsma, H.3    van Nostrum, C.F.4    Jiskoot, W.5    Crommelin, D.J.A.6
  • 38
    • 84876011658 scopus 로고    scopus 로고
    • Mechanistic studies on the degradation and protein release characteristics of poly(lactic-co-glycolic-co-hydroxymethylglycolic acid) nanospheres
    • Samadi N., van Nostrum C.F., Vermonden T., Amidi M., Hennink W.E. Mechanistic studies on the degradation and protein release characteristics of poly(lactic-co-glycolic-co-hydroxymethylglycolic acid) nanospheres. Biomacromolecules 2013, 14:1044-1053.
    • (2013) Biomacromolecules , vol.14 , pp. 1044-1053
    • Samadi, N.1    van Nostrum, C.F.2    Vermonden, T.3    Amidi, M.4    Hennink, W.E.5
  • 39
    • 84922749845 scopus 로고    scopus 로고
    • Biocompatibility of poly(d,l-lactic-co-hydroxymethyl glycolic acid) microspheres after subcutaneous and subcapsular renal injection
    • Kazazi-Hyseni F., Zandstra J., Popa E., Goldschmeding R., Lathuile A., Veldhuis G., et al. Biocompatibility of poly(d,l-lactic-co-hydroxymethyl glycolic acid) microspheres after subcutaneous and subcapsular renal injection. Int. J. Pharm. 2015, 482:99-109.
    • (2015) Int. J. Pharm. , vol.482 , pp. 99-109
    • Kazazi-Hyseni, F.1    Zandstra, J.2    Popa, E.3    Goldschmeding, R.4    Lathuile, A.5    Veldhuis, G.6
  • 40
    • 84922286412 scopus 로고    scopus 로고
    • Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: In vivo tracking and evaluation of antigen-specific CD8+ T cell immune response
    • Rahimian S., Kleinovink J.W., Fransen M.F., Mezzanotte L., Gold H., Wisse P., et al. Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: In vivo tracking and evaluation of antigen-specific CD8+ T cell immune response. Biomaterials 2015, 37:469-477.
    • (2015) Biomaterials , vol.37 , pp. 469-477
    • Rahimian, S.1    Kleinovink, J.W.2    Fransen, M.F.3    Mezzanotte, L.4    Gold, H.5    Wisse, P.6
  • 41
    • 77956304534 scopus 로고    scopus 로고
    • Macrophages recognize size and shape of their targets
    • Doshi N., Mitragotri S. Macrophages recognize size and shape of their targets. PloS One 2010, 5:e10051.
    • (2010) PloS One , vol.5 , pp. e10051
    • Doshi, N.1    Mitragotri, S.2
  • 42
    • 33744490409 scopus 로고    scopus 로고
    • Functionalized poly(alpha-hydroxy acid)s via ring-opening polymerization: Toward hydrophilic polyesters with pendant hydroxyl groups
    • Leemhuis M., van Nostrum C., Kruijtzer J., Zhong Z., ten Breteler M., Dijkstra P., et al. Functionalized poly(alpha-hydroxy acid)s via ring-opening polymerization: Toward hydrophilic polyesters with pendant hydroxyl groups. Macromolecules 2006, 39:3500-3508.
    • (2006) Macromolecules , vol.39 , pp. 3500-3508
    • Leemhuis, M.1    van Nostrum, C.2    Kruijtzer, J.3    Zhong, Z.4    ten Breteler, M.5    Dijkstra, P.6
  • 44
    • 0030699113 scopus 로고    scopus 로고
    • A new strategy to determine the actual protein content of poly(lactide-co-glycolide) microspheres
    • Sah H. A new strategy to determine the actual protein content of poly(lactide-co-glycolide) microspheres. J. Pharm. Sci. 1997, 86:1315-1318.
    • (1997) J. Pharm. Sci. , vol.86 , pp. 1315-1318
    • Sah, H.1
  • 45
    • 0030273141 scopus 로고    scopus 로고
    • The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching
    • Rolink A., Melchers F., Andersson J. The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching. Immunity 1996, 5:319-330.
    • (1996) Immunity , vol.5 , pp. 319-330
    • Rolink, A.1    Melchers, F.2    Andersson, J.3
  • 46
    • 0032054727 scopus 로고    scopus 로고
    • Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy
    • Clarke P., Mann J., Simpson J.F., Rickard-Dickson K., Primus F.J. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res. 1998, 58:1469-1477.
    • (1998) Cancer Res. , vol.58 , pp. 1469-1477
    • Clarke, P.1    Mann, J.2    Simpson, J.F.3    Rickard-Dickson, K.4    Primus, F.J.5
  • 47
    • 46749119051 scopus 로고    scopus 로고
    • Role of particle size in phagocytosis of polymeric microspheres
    • Champion J.A., Walker A., Mitragotri S. Role of particle size in phagocytosis of polymeric microspheres. Pharm. Res. 2008, 25:1815-1821.
    • (2008) Pharm. Res. , vol.25 , pp. 1815-1821
    • Champion, J.A.1    Walker, A.2    Mitragotri, S.3
  • 48
    • 38549156628 scopus 로고    scopus 로고
    • How to achieve sustained and complete protein release from PLGA-based microparticles?
    • Giteau A., Venier-Julienne M.C., Aubert-Pouessel A., Benoit J.P. How to achieve sustained and complete protein release from PLGA-based microparticles?. Int. J. Pharm. 2008, 350:14-26.
    • (2008) Int. J. Pharm. , vol.350 , pp. 14-26
    • Giteau, A.1    Venier-Julienne, M.C.2    Aubert-Pouessel, A.3    Benoit, J.P.4
  • 49
    • 0038445582 scopus 로고    scopus 로고
    • Biodegradable microspheres for protein delivery
    • Sinha V., Trehan A. Biodegradable microspheres for protein delivery. J. Control Release 2003, 90:261-280.
    • (2003) J. Control Release , vol.90 , pp. 261-280
    • Sinha, V.1    Trehan, A.2
  • 50
    • 47349130974 scopus 로고    scopus 로고
    • Analysis of initial burst in PLGA microparticles
    • Allison S.D. Analysis of initial burst in PLGA microparticles. Exp. Opin. Drug Deliv. 2008, 5:615-628.
    • (2008) Exp. Opin. Drug Deliv. , vol.5 , pp. 615-628
    • Allison, S.D.1
  • 51
    • 0035850221 scopus 로고    scopus 로고
    • On the importance and mechanisms of burst release in matrix-controlled drug delivery systems
    • Huang X., Brazel C.S. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J. Control Release 2001, 73:121-136.
    • (2001) J. Control Release , vol.73 , pp. 121-136
    • Huang, X.1    Brazel, C.S.2
  • 52
    • 0342265154 scopus 로고    scopus 로고
    • Effect of preparation conditions on morphology and release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion method
    • Yang Y., Chung T., Bai X., Chan W. Effect of preparation conditions on morphology and release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion method. Chem. Eng. Sci. 2000, 55:2223-2236.
    • (2000) Chem. Eng. Sci. , vol.55 , pp. 2223-2236
    • Yang, Y.1    Chung, T.2    Bai, X.3    Chan, W.4
  • 53
    • 0035255916 scopus 로고    scopus 로고
    • Ping Ng N. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method
    • Yang Y., Chung T. Ping Ng N. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials 2001, 22:231-241.
    • (2001) Biomaterials , vol.22 , pp. 231-241
    • Yang, Y.1    Chung, T.2
  • 54
    • 34948881276 scopus 로고    scopus 로고
    • In vitro hydrolytic degradation of hydroxyl-functionalized poly(alpha-hydroxy acid)s
    • Leemhuis M., Kruijtzer J.A.W., van Nostrurn C.F., Hennink W.E. In vitro hydrolytic degradation of hydroxyl-functionalized poly(alpha-hydroxy acid)s. Biomacromolecules 2007, 8:2943-2949.
    • (2007) Biomacromolecules , vol.8 , pp. 2943-2949
    • Leemhuis, M.1    Kruijtzer, J.A.W.2    van Nostrurn, C.F.3    Hennink, W.E.4
  • 56
    • 84892421320 scopus 로고    scopus 로고
    • Local immunomodulation for cancer therapy Providing treatment where needed
    • Fransen M.F., Ossendorp F., Arens R., Melief C.J.M. Local immunomodulation for cancer therapy Providing treatment where needed. Oncoimmunol 2013, 2:e26493.
    • (2013) Oncoimmunol , vol.2 , pp. e26493
    • Fransen, M.F.1    Ossendorp, F.2    Arens, R.3    Melief, C.J.M.4
  • 57
    • 33645225168 scopus 로고    scopus 로고
    • The use of oil adjuvants in therapeutic vaccines
    • S2-S44-5
    • Aucouturier J., Ascarateil S., Dupuis L. The use of oil adjuvants in therapeutic vaccines. Vaccine 2006, 24(Suppl 2). S2-S44-5.
    • (2006) Vaccine , vol.24 , Issue.Suppl 2
    • Aucouturier, J.1    Ascarateil, S.2    Dupuis, L.3
  • 58
    • 18744364924 scopus 로고    scopus 로고
    • Design and selection of vaccine adjuvants: animal models and human trials
    • Alving C.R. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 2002, 20(Suppl 3):S56-S64.
    • (2002) Vaccine , vol.20 , Issue.Suppl 3 , pp. S56-S64
    • Alving, C.R.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.